ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2015
Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Psychometric properties of the EQ-5D-5L: a systematic review of the literature.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review.Frontiers in public health · 2021Pooled it
- Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review.PharmacoEconomics · 2020Pooled it
- Utilizing technology for diet and exercise change in complex chronic conditions across diverse environments (U-DECIDE): feasibility randomised controlled trial.BMC health services research · 2024Trial
- Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Trial
- Cost-Effective Analysis of Ultrasound Evaluation for Hydronephrosis in Stage 3 and Stage 4 POP.International urogynecology journal · 2026Article
- Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation.Pilot and feasibility studies · 2026Article
- Psychometric properties comparison of EQ-5D-Y-3L and CHU9D in children and adolescents across different BMI classifications in Jiangsu, China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among patients with diabetes in China.Health and quality of life outcomes · 2025Article
- Health-related quality of life among the patients undergoing dialysis in a tertiary care teaching hospital in Southern India.The Indian journal of medical research · 2025Article
- Validation and comparison of EQ-5D-5L and SF-6Dv1 in myopic patients requiring corneal refractive surgery in China.Health and quality of life outcomes · 2025Article
- Socio-demographic characteristics associated with SF-6D v2 utility scores in patients undergoing dialysis in China: contributions of the quantile regression.Health and quality of life outcomes · 2025Article
- Comparison of the measurement properties of EQ-5D-5L and SF-6Dv2 in Chinese patients on dialysis.Health and quality of life outcomes · 2025Article
- Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China.Frontiers in oncology · 2025Article
- Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China.Applied health economics and health policy · 2024Article
- Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT).The Lancet regional health. Europe · 2024Article
- Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.PharmacoEconomics · 2024Article
- Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study was to compare the performance of the 5-level EuroQol 5-dimension (EQ-5D-5L) and the Short Form 6-dimension (SF-6D) instruments in assessing patients with end-stage renal disease (ESRD) in Singapore.
methodsIn a cross-sectional study, ESRD patients attending a tertiary hospital were interviewed using a battery of questionnaires including the EQ-5D-5L, the kidney disease quality of life instrument (KDQOL-36), and questions assessing dialysis history and socio-demographic characteristics. We reviewed patients' medical records for their clinical information. We assessed the construct validity of the EQ-5D-5L and SF-6D index scores and compared their ability to distinguish between patients differing in health status and the magnitude of between-group difference they quantified.
resultsOne hundred and fifty ESRD patients on dialysis (mean age, 60.1 years; female, 48.7%) participated in the study. Both EQ-5D-5L and SF-6D demonstrated satisfactory known-groups validity; the EQ-5D-5L was more sensitive to differences in clinical outcomes and the SF-6D was more sensitive to differences in health outcomes measured by KDQOL scales. The intraclass correlation coefficient between the measures was 0.36. The differences in the EQ-5D-5L index score for patients in better and worse health status were greater than those measured by the SF-6D index score.
conclusionsBoth EQ-5D-5L and SF-6D are valid instruments for assessing ESRD patients. However, the two preference-based measures cannot be used interchangeably and it appears that EQ-5D-5L would lead to more favorable cost-effectiveness results than SF-6D if they are used in economic evaluations of interventions for ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.